Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05895279 · ClinicalTrials.gov registry record · NA
Assessment of Research Digest Impact for Minority with Prostate Cancer, MiCAP Phase III Study
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 220
- Enrollment target
NCT05895279: Completed NA study, sponsored by Mayo Clinic.
NCT05895279 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 220 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05895279, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 220 participants
- Enrollment target
Study Summary
This phase III trial determines how well the Minority Prostate Cancer (MiCaP) Research Digest works in providing information to black men about the latest prostate cancer research. MiCaP Research Digest may be an effective method to help people learn about prostate cancer.This goal of this trial is to create educational programming that helps Black men make informed decisions about their prostate healthcare since Black men are diagnosed with prostate cancer more than any other race or ethnicity.
Primary Outcome
Using the Minority Prostate Cancer (MiCaP) survey developed for this study, participants are asked 10 questions regarding access to medical services and general health with a yes/no response.
Interventions
- OTHER Survey Administration
- OTHER Media Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2021-08-02 |
| Est. Completion | 2021-10-01 |
| Phase | NA |
What the finished NCT05895279 record still lists
NCT05895279 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which Survey Administration is the first listed.
NCT05895279 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05895279 about?
NCT05895279 is a clinical study titled "Assessment of Research Digest Impact for Minority with Prostate Cancer, MiCAP Phase III Study". This phase III trial determines how well the Minority Prostate Cancer (MiCaP) Research Digest works in providing information to black men about the latest prostate cancer research. MiCaP Research Digest may be an effective method to help people learn about prostate cancer.This goal of this trial is ...
What is the current status of trial NCT05895279?
This trial is currently completed. It is a NA study. The enrollment target is 220 participants. The study started on 2021-08-02. Estimated completion is 2021-10-01.
What interventions are being tested in trial NCT05895279?
The interventions under investigation include: Survey Administration (OTHER), Media Intervention (OTHER).
Who is sponsoring clinical trial NCT05895279?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05895279's enrollment target sits among peer trials
220 481st of 2000 higher than 1,516 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI